|
von PR&D am 24.10.08, 13:57 in Handel + Wirtschaft + Finanzen
|
|
(openpresse)
GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyloid.
As part of the agreement GSK is acquiring exclusive rights to develop and commercialise two Alzheimer's disease vaccine candidates
|